ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Abatacept"

  • Abstract Number: 024 • 2020 Pediatric Rheumatology Symposium

    Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma

    Suzanne Li1, Sarah Ishaq 2, Mary Buckley 3, Kathryn Torok 4, Barbara Edelheit 5, Kaleo Ede 6 and C. Egla Rabinovich 7, 1Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 2Montclair State University, montclair, 3Duke University, Durham, 4Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, 5CT Children's Medical Center, Hartford, 6Phoenix Children's Hospital, Phoenix, 7Duke University Hospital, Durham

    Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
  • Abstract Number: L09 • 2019 ACR/ARP Annual Meeting

    A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial

    Merete Lund Hetland1, Espen A Haavardsholm 2, Anna Rudin 3, Dan Nordström 4, Mike Nurmohamed 5, Bjorn Gudbjornsson 6, Jon Lampa 7, Kim Hørslev-Petersen 8, Till Uhlig 9, Gerdur Grondal 10, Mikkel Østergaard 11, Marte Heiberg 2, Jos Twisk 12, Kristina Lend 7, Simon Krabbe 13, Joakim Lindqvist 7, Anna-Karin Ekwall 14, Kathrine Lederballe Grøn 15, Meliha Kapetanovic 16, Francesca Faustini 7, Riitta Tuompo 17, Tove Lorenzen 18, Giovanni Cagnotto 19, Eva Baecklund 20, Oliver Hendricks 21, Daisy Vedder 22, Tuulikki Sokka-isler 23, Tomas Husmark 24, Maud-Kristine Aga Ljoså 25, Eli Brodin 26, Torkell Ellingsen 27, Annika Söderbergh 28, Milad Rizk 29, Åsa Reckner 30, Line Uhrenholt 31, Per Larsson 32, Soeren Just 33, David Stevens 34, Trine Laurberg 35, Gunnstein Bakland 36, Inge Christoffer Olsen 37, Ronald van Vollenhoven 38 and The NORD-STAR Study Group 39, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 2Diakonhjemmet Hospital, Oslo, Norway, 3Dept Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden, 4Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, 5Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, 6Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 7Karolinska Institutet, Stockholm, Sweden, 8Department of Rheumatology, King Christian X's Hospital for Rheumatic Diseases Graasten, Denmark, Graasten, Denmark, 9Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 10Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, 11Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 12Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, Netherlands, 13Rigshospitalet, København, Denmark, 14University of Gothenburg, Kullavik, Sweden, 15Rigshospitalt Glostrup, Glostrup, Denmark, 16Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, 17Helsinki University Hospital, Helsinki, Finland, 18Reumatologi, Regionshospitalet Silkeborg, Kolding, Denmark, 19Lund University, Malmö, Sweden, 20Uppsala University, Uppsala, Sweden, 21Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 22Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, 23Jyvaskyla Central Hospital, Jyvaskyla, Finland, 24Rheumatology Clinic, Falun, Sweden, 25Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, 26Haukeland University Hospital, Bergen, Norway, 27Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, 28Örebro University Hospital, Ôrebro, Sweden, 29Västmanlands Hospital, Västerås, Sweden, 30Rheumatology Department, Linkoping, Sweden, 31Aalborg Universitetshospital, Aalborg, Denmark, 32Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 33Odense University Hospital, Odense, 34St. Olav's University Hospital, Trondheim, Norway, 35Aarhus University Hospital, Aarhus, Denmark, 36University Hospital of North Norway, Tromsø, Norway, 37Oslo University Hospital, Oslo, Norway, 38Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, 39Site investigators in all participating countries, Stockholm, Sweden

    Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established. The primary aim was to assess and…
  • Abstract Number: L11 • 2019 ACR/ARP Annual Meeting

    Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Thomas W.J. Huizinga 4, Gustavo Citera 5, Clifton Bingham 6, Subhashis Banerjee 7, Benjamin Soule 8, Marleen Nys 9, Sean Connolly 10, Robert Wong 10, Kuan-Hsiang Gary Huang 7 and Roy Fleischmann 11, 1University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, 4Leiden University Medical Center, Leiden, Netherlands, 5Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 6Johns Hopkins University, Baltimore, 7Bristol-Myers Squibb, Princeton, NJ, 8Bristol-Myers Squibb, Princeton, New Jersey, 9Bristol-Myers Squibb, Braine L'Alleud, Belgium, 10Bristol-Myers Squibb, Princeton, 11Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
  • Abstract Number: 1425 • 2019 ACR/ARP Annual Meeting

    Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial

    Thomas Huizinga1, René Toes 1, Michael Weinblatt 2, Michael Schiff 3, Roy Fleischmann 4, Yedid Elbez 5, Sean Connolly 6, Michael Maldonado 6 and Sheng Gao 6, 1Leiden University Medical Center, Leiden, Netherlands, 2Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, 3University of Colorado, Denver, CO, 4Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 5Excelya, Boulogne-Billancourt, France, 6Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a marker for early, erosive RA.1 In the Abatacept (ABA) versus adaliMumab (ADA) comParison in bioLogic-naïvE RA subjects with…
  • Abstract Number: 1429 • 2019 ACR/ARP Annual Meeting

    Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis

    Omar Valenzuela 1, Sebastian Ibanez2, Maria Paz Poblete 3, Claudia Mardones 2, Francisco Silva 2, Maria Jose Villar 2 and Katherine Mogollones 1, 1Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile, 2Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, 3Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile

    Background/Purpose: Since January 2016, Chilean patients with rheumatoid arthritis (RA), with severe activity despite the use of 3 DMARDs for at least 6 months, have guaranteed access…
  • Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting

    Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease

    Sho Sasaki1, Akira Ishii 2, Mai Sugiyama 2, Yuto Izumi 2, Yoko Nakagome 2, Kazuki Hirano 3, Takayoshi Kurabayashi 1, Noriko Sasaki 2, Chiho Yamada 2 and Shinji Sato 4, 1Tokai Universitiy School of Medicine, Isehara, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Tokai University School of Medicine, Isehara, 4Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan

    Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…
  • Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting

    Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis

    MASAOMI YAMASAKI1, 1Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

    Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…
  • Abstract Number: 1815 • 2019 ACR/ARP Annual Meeting

    Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials

    Nicolino Ruperto1, Daniel J. Lovell 2, John Bohnsack 3, Johannes Breedt 4, Michel Fischbach 5, Thomas Lutz 6, Kirsten Minden 7, Tatiana Miraval 8, Mahmood M. T. M. Ally 9, Nadina Rubio-Pérez 10, Elisabeth Gervais 11, Riana van Zyl 12, Robert Wong 13, Marleen Nys 14, Alberto Martini 15 and Hermine Brunner 16, 1Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 2Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, 3University of Utah School of Medicine, Salt Lake City, UT, 4Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa, 5Pédiatrie 1, CHU Hautepierre, Strasbourg, France, 6Heidelberg University Hospital, Heidelberg, Germany, 7German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, 8Clínica San Gabriel, Lima, Peru, 9University of Pretoria, Pretoria, South Africa, 10University Hospital Dr. José Eleuterio González, Monterrey, Mexico, 11CHU de Poitiers, Rheumatology, Poitiers, France, 12University of the Free State, Bloemfontein, South Africa, 13Bristol-Myers Squibb, Princeton, 14Bristol-Myers Squibb, Braine L’Alleud, Belgium, 15IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 16Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: In EU, abatacept (ABA) with MTX is approved in patients (pts) with polyarticular-course JIA (pJIA), as young as 2 years (SC) and 6 years…
  • Abstract Number: 1928 • 2019 ACR/ARP Annual Meeting

    Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis

    Antonio Julià1, Maria Lopez Lasanta 2, Antonio Gómez 3, Irene Bonafonte 4, Raimon Sanmartí 5, Carlos Marras 6, José Manuel Pina 7, Susana Romero-Yuste 8, Raul Veiga 9, Pilar Navarro 9, Carmen Moragues Pastor 10, Silvia Martínez 11, Francisco J. De Toro 12, Amalia Sanchez 13, Dacia Cerdà 14, Alejandro Prada 15, Alba Erra 16, Jordi Monfort 17, A. Urruticoechea-Arana 18, Núria Palau 19, Raquel Lastra 20, Raúl Tortosa 3, Andrea Pluma 21 and Sara Marsal 22, 1Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, 2Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, 3Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, 4Vall Hebron Hospital Research Institute, Barcelona, Spain, 5Hospital Clínic, Barcelona, Barcelona, Spain, 6Hospital Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, 7Hospital de Barbastro, Huesca, Barbastro, Huesca, Spain, 8Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, 9Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, 10Platò Hospital, Barcelona, Spain, Barcelona, Spain, 11Hospital Universitari Mútua Terrassa, Terrassa, Spain, 12University Hospital A Coruña, A Coruña, Spain, 13Hospital Universitario Lucus Augusti, Lugo, Lugo, Spain, 14Hospital Moisès Broggi, Sant Joan Despí, Sant Joan Despí, Spain, 15Hospital Universitario Torrejón de Ardoz, Torrejón de Ardoz, Spain, 16Hospital Sant Rafael, Barcelona, Barcelona, Spain, 17Hospital del Mar, Barcelona, Spain, 18HU Can Misses, Ibiza, Spain, 19Hospital Vall Hebrón Barcelona, Barcelona, Spain, 20Hospital Vall Hebron, Barcelona, Barcelona, Spain, 21Hospital Universitari Vall d'Hebron, Barcelona, Spain, 22Vall d’Hebron Hospital, Barcelona, Catalonia, Spain

    Background/Purpose: Abatacept (CTLA4-Ig) is an approved biological therapy for the treatment of rheumatoid arthritis (RA). Similar to other biological agents, most patients (50-60%) respond significantly…
  • Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting

    Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Kuan-Hsiang Gary Huang 7, Sean Connolly 7, Yedid Elbez 8, Karissa Lozenski 9 and Roy Fleischmann 10, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, NJ, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Princeton, 10Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
  • Abstract Number: 2707 • 2019 ACR/ARP Annual Meeting

    Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study

    Hermine Brunner1, Nikolay Tzaribachev 2, Ingrid Louw 3, Jordi Antón 4, Diego Viola 5, Bernard Lauwerys 6, Rubèn J Cuttica 7, Pierre Quartier 8, Elisabeth Gervais 9, Alexandre Belot 10, Kirsten Minden 11, Thomas Lutz 12, Rolando Cimaz 13, Mahmood M. T. M. Ally 14, Riana van Zyl 15, Inmaculada Calvo Penadés 16, Joe Zhuo 17, Robert Wong 18, Marleen Nys 19, Yedid Elbez 20, Alberto Martini 21, Daniel J. Lovell 22 and Nicolino Ruperto 23, 1Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 3Panorama Medical Centre, Parow, South Africa, 4Hospital Sant Joan de Déu, Barcelona, Spain, 5CAICI Institute, Rosario City, Santa Fe State, Argentina, 6Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, 7Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, 8Necker Hospital, Paris, France, 9CHU de Poitiers, Rheumatology, Poitiers, France, 10Centre Hospitalier Universitaire de Lyon, Lyon, France, 11German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, 12Heidelberg University Hospital, Heidelberg, Germany, 13Meyer Children's Hospital in Florence, Florence, Italy, 14University of Pretoria, Pretoria, South Africa, 15University of the Free State, Bloemfontein, South Africa, 16Hospital Univ. La Fe, Valencia, Spain, 17Bristol-Myers Squibb, Princeton, NJ, 18Bristol-Myers Squibb, Princeton, 19Bristol-Myers Squibb, Braine L’Alleud, Belgium, 20Excelya, Boulogne-Billancourt, France, 21IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 22Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, 23Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy

    Background/Purpose: Efficacy of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label, Phase III international study (NCT01844518).1 Pediatric patient-reported outcomes…
  • Abstract Number: 249 • 2019 ACR/ARP Annual Meeting

    Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity

    Damemarie Paul 1, Xue Han2, Irina Yermilov 3, Sarah Gibbs 3 and Michael Broder 3, 1Bristol-Myers Squibb, Lawrenceville, NJ, 2Bristol-Myers Squibb Company, Princeton, NJ, 3Partnership for Health Analytic Research, LLC, Beverly Hills, CA

    Background/Purpose: Abatacept is recommended as first-line biologic therapy in adult patients with moderate to severe RA. We aimed to assess real-world 1-year treatment persistence in…
  • Abstract Number: 2708 • 2019 ACR/ARP Annual Meeting

    Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials

    Hermine Brunner1, Nikolay Tzaribachev 2, Ingrid Louw 3, Alberto Berman 4, Inmaculada Calvo Penadés 5, Jordi Antón 6, Francisco Ávila-Zapata 7, Rubèn J Cuttica 8, Gerd Horneff 9, Robert Wong 10, Mehmooda Shaikh 11, Johanna Mora 11, Marleen Nys 12, Daniel J. Lovell 13, Alberto Martini 14 and Nicolino Ruperto 15, 1Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 3Panorama Medical Centre, Parow, South Africa, 4Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, 5Hospital Univ. La Fe, Valencia, Spain, 6Hospital Sant Joan de Déu, Barcelona, Spain, 7Star Medica Hospital, Merida, Yucatán, Mexico, 8Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, 9Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 10Bristol-Myers Squibb, Princeton, 11Bristol-Myers Squibb, Princeton, NJ, 12Bristol-Myers Squibb, Braine L’Alleud, Belgium, 13Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, 14IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 15Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy

    Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…
  • Abstract Number: 546 • 2019 ACR/ARP Annual Meeting

    Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX

    René Toes1, Thomas Lehman 2, Joshua Bryson 3, Amy Min Kim 2, Sandhya Balachandar 2, Sumanta Mukherjee 2, Michael Maldonado 2, Sean Connolly 2 and Thomas Huizinga 1, 1Leiden University Medical Center, Leiden, Netherlands, 2Bristol-Myers Squibb, Princeton, NJ, 3Bristol-Myers Squibb, Princeton

    Background/Purpose: An emerging concept of “immunologic remission” in RA raises questions about the relevance of the RA autoantibody profile in patients (pts) who are otherwise…
  • Abstract Number: 2770 • 2019 ACR/ARP Annual Meeting

    Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis Patients in Remission

    Joanna Kedra1, Philippe Dieudé 2, Hubert Marotte 3, Alexandre Lafourcade 4, Emilie Ducourau 5, Thierry Schaeverbeke 6, Aleth Perdriger 7, Martin SOUBRIER 8, Jacques Morel 9, Arnaud Constantin 10, Emmanuelle Dernis 11, Valérie Royant 12, Jean-Hugues Salmon 13, Thao Pham 14, Jacques-Eric Gottenberg 15, Edouard Pertuiset 16, Maxime Dougados 17, Valérie Devauchelle Pensec 18, Philippe Gaudin 19, gregoire Cormier 20, Philippe Goupille 21, Xavier Mariette 22, Francis Berenbaum 23, Didier Alcaix 24, Sid-Ahmed Rouidi 25, Jean-Marie Berthelot 26, Agnès Monnier 27, Christine Piroth 28, Frédéric Lioté 29, Vincent Goeb 30, Cécile Gaujoux-Viala 31, Isabelle Chary-Valckenaere 32, David Hajage 4, Florence Tubach 33 and Bruno Fautrel 34, 1Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, 2Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, 3University Hospital, St Etienne, France, 4Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, 5Rheumatology Department, CHR Orléans, Orléans, France, 6FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, 7Rheumatology department, Rennes University Hospital, France, Rennes, France, 8CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, 9CHU MONTPELLIER, MONTPELLIER, France, 10Hôpital Pierre-Paul Riquet, Toulouse, France, 11Rheumatology Department, Le Mans Central Hospital, Le Mans, France, 12Rheumatology Department, Chartres Hospital, Chartres, France, 13Rheumatology, Reims University Hospital, Reims, Reims, France, 14Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, 15Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 16Rheumatology Department, Pontoise Hospital, Pontoise, France, Pontoise, France, 17Cochin Hospital, Paris, France, 18University Hospital of Brest, Brest, France, 19Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, 20CHD Vendée, La Roche sur Yon, France, 21Tours University-Hospital, Tours, France, Tours, France, 22Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 23Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France, 24Rheumatology Department, Le Havre Hospital, Le Havre, 25Rheumatology Department, Dreux, France, 26University Hospital, Nantes, France, 27Internal Medicine Department, CH Côte Basque, Bayonne, France, 28Rheumatology Department, Dijon Hospital, Dijon, France, 29Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France, 30Rheumatology Department, Amiens University Hospital, Amiens, France, 31Nîmes University Hospital, Nîmes, France, 32Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, 33Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, 34Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France

    Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARD) tapering is proposed by clinical practice guidelines in rheumatoid arthritis (RA) patients in sustained remission. However, no randomized…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.